A Phase 1b/2 Study of Entospletinib (ENTO) in Patients with Acute Myeloid Leukemia (AML) > Age 60 with MLL gene rearrangements and/or MLL-Partial Tandem Duplications (MLL-PTD)
The purpose of this study is to determine the safety and tolerability of the experimental drug, entospletinib (ENTO, GS-9973), alone and in combination with Azacitidine (Aza, Vidaza).
Acute Myeloid Leukemia (AML)
-Participating in the Beat AML umbrella study master protocol (reference IRB# 16475)
-Newly diagnosed with AML
-Age 60 years or older at time of diagnosis
-MLL gene rearrangement
60 - n/a
Healthy Volunteers Needed
Duration of Participation
Study participation may include up to 5 years of study drug treatment and 30 days after you stop taking the study drug.
Clinical Trials Information Line
Beat AML, LLC, a division of the Leukemia and Lymphoma Society, Inc
Supported by: Gilead Pharmaceuticals